 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Celox Laboratories, Inc.
 |
Celox Laboratories, Inc. |
 |
 |
 |
PROFILE |
 |
Celox Laboratories makes serum-free products used as mediums for in vitro human and animal cell growth. Celox's products aid in the development of vaccines, antibodies, interferons, and other cell-based compounds. Its more than 25 products include growth mediums for culturing embryonic kidney cells, producing veterinary vaccines, and freezing cells. Celox sells to academic, pharmaceutical, and commercial laboratories throughout Asia, Europe, Latin America, and North America; it also has distribution agreements with other biotech firms. Its new product, ViaStem, is designed to preserve stem cells for bone-marrow transplants; clinical tests for ViaStem have been put on hold. CEO Milo Polovina owns nearly 25% of Celox.
COMPETITION |
 |
Becton, Dickinson and Company (BDX)
Boehringer Ingelheim GmbH (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: August
2000 Sales (mil.): 0.20
1-Yr. Sales Growth: 1.5%
Employees: 3
Revenue per employee: $66,666.67
KEY PEOPLE |
 |
Milo R. Polovina
CEO
Milo R. Polovina
CFO
CONTACT INFO |
 |
1311 Helmo Ave.
St. Paul, MN 55128
US
Phone: 651-730-1500
Fax: 651-730-8900
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |